New biologic combo shows promise for lupus kidney patients
NCT ID NCT07340463
First seen Jan 16, 2026 · Last updated May 07, 2026 · Updated 13 times
Summary
This study tests whether newer biologic drugs (belimumab or telitacicept) can control active lupus kidney disease better than the standard medication mycophenolate mofetil. About 50 adults with biopsy-confirmed lupus nephritis will receive one of three treatments for 6 months. The goal is to see if more patients achieve complete kidney remission with the biologic-based regimens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Ethics Committee of the General Hospital of Eastern Theater Command of the People's Liberation Army
RECRUITINGNanjing, Jiangsu, 210016, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.